Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 826 to 840 of 1334 results for long term conditions

  1. Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer (TA784)

    Evidence-based recommendations on niraparib (Zejula) for treating relapsed, platinum-sensitive high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer in adults.

  2. Pegaspargase for treating acute lymphoblastic leukaemia (TA408)

    Evidence-based recommendations on pegaspargase (Oncaspar) for treating acute lymphoblastic leukaemia.

  3. Intraoperative tests (RD‑100i OSNA system and Metasin test) for detecting sentinel lymph node metastases in breast cancer (HTG315)

    Evidence-based recommendations on the RD-100i OSNA system and Metasin test for detecting sentinel lymph node metastases in people having breast cancer surgery.

  4. Menopause (QS143)

    This quality standard covers diagnosing and managing menopause in women, trans men and non-binary people registered female at birth, including those who have premature ovarian insufficiency (menopause before the age of 40, which can occur naturally or as a result of medical or surgical treatment). It describes high-quality care in priority areas for improvement.

  5. Type 2 diabetes mellitus in adults: high-strength insulin glargine 300 units/ml (Toujeo) (ESNM65)

    Summary of the evidence on high-strength insulin glargine 300 units/ml (Toujeo) for type 2 diabetes mellitus to inform local NHS planning and decision-making

  6. Smart One for measuring lung function (MIB96)

    NICE has developed a medtech innovation briefing (MIB) on Smart One for measuring lung function .

  7. Tirzepatide for treating type 2 diabetes (TA924)

    Evidence-based recommendations on tirzepatide (Mounjaro) for type 2 diabetes in adults.

  8. Dupilumab for treating moderate to severe prurigo nodularis (TA955)

    Evidence-based recommendations on dupilumab (Dupixent) for treating moderate to severe prurigo nodularis in adults when systemic treatment is suitable.

  9. What is the long-term effect of laparoscopic cholecystectomy on outcomes that are important to patients?

    Recommendation ID CG188/5 Question What is the long-term effect of laparoscopic cholecystectomy on outcomes that are...

  10. OCS Heart system for heart transplant (MIB86)

    NICE has developed a medtech innovation briefing (MIB) on OCS Heart system for heart transplant .

  11. Sunlight exposure: risks and benefits (NG34)

    This guideline covers how to communicate the risks and benefits of natural sunlight exposure (specifically, the ultraviolet rays UVA and UVB) to help people understand why they may need to modify their behaviour to reduce their risk of skin cancer and vitamin D deficiency.

  12. Coexisting severe mental illness and substance misuse: community health and social care services (NG58)

    This guideline covers how to improve services for people aged 14 and above who have been diagnosed as having coexisting severe mental illness and substance misuse. The aim is to provide a range of coordinated services that address people’s wider health and social care needs, as well as other issues such as employment and housing.

  13. Pneumonia: diagnosis and management (QS110)

    This quality standard covers diagnosing, assessing and treating community-acquired and hospital-acquired pneumonia in babies over 1 month (corrected gestational age), children, young people and adults. It describes high-quality care in priority areas for improvement. It does not cover ventilator associated pneumonia or COVID-19 pneumonia.

  14. Artificial intelligence (AI) technologies to aid opportunistic detection of vertebral fragility fractures: early value assessment (HTG760)

    Early value assessment (EVA) guidance on artificial intelligence (AI) technologies to aid opportunistic detection of vertebral fragility fractures.

  15. Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (TA870)

    Evidence-based recommendations on ixazomib with lenalidomide and dexamethasone for relapsed or refractory multiple myeloma.